Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason A Roberts

Showing results (1-10 of 681) with videos related to

Pageof 69
Sort By:
Critical Care Medicine|January 17, 2018
Beta-Lactam Therapeutic Drug Monitoring in the Critically Ill Children: Big Solution for Infections in Small People?Jason A Roberts
The Lancet. Infectious Diseases|December 3, 2014
Therapeutic drug monitoring of antibiotics--author's replyJason A Roberts, ,
Current Pharmaceutical Biotechnology|May 11, 2011
Using PK/PD to optimize antibiotic dosing for critically ill patientsJason A Roberts
Current Pharmaceutical Biotechnology|March 22, 2012
Relevance of pharmacokinetics to antibiotic dosing in critically ill patientsJason A Roberts
Seminars in Respiratory and Critical Care Medicine|December 21, 2007
Optimizing use of beta-lactam antibiotics in the critically illJason A Roberts, Jeffrey Lipman
Critical Care Medicine|December 25, 2012
Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibilityJason A Roberts, Jeffrey Lipman
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 17, 2012
Editorial commentary: Closing the loop--a colistin clinical study to confirm dosing recommendations from PK/PD modelingJason A Roberts, Jeffrey Lipman
Clinical Pharmacokinetics|August 4, 2006
Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsisJason A Roberts, Jeffrey Lipman
Critical Care Medicine|February 25, 2009
Pharmacokinetic issues for antibiotics in the critically ill patientJason A Roberts, Jeffrey Lipman
Critical Care (London, England)|May 10, 2007
Conclusions regarding the efficacy of treatments for neuroleptic malignant syndrome should be tempered given poor quality data, regardless of the analysis conductedDarren M Roberts, Jason A Roberts
Pageof 69

Showing results (1-10 of 681) with videos related to

Sort By:
Pageof 69
Critical Care Medicine|January 17, 2018
Beta-Lactam Therapeutic Drug Monitoring in the Critically Ill Children: Big Solution for Infections in Small People?Jason A Roberts
The Lancet. Infectious Diseases|December 3, 2014
Therapeutic drug monitoring of antibiotics--author's replyJason A Roberts, ,
Current Pharmaceutical Biotechnology|May 11, 2011
Using PK/PD to optimize antibiotic dosing for critically ill patientsJason A Roberts
Current Pharmaceutical Biotechnology|March 22, 2012
Relevance of pharmacokinetics to antibiotic dosing in critically ill patientsJason A Roberts
Seminars in Respiratory and Critical Care Medicine|December 21, 2007
Optimizing use of beta-lactam antibiotics in the critically illJason A Roberts, Jeffrey Lipman
Critical Care Medicine|December 25, 2012
Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibilityJason A Roberts, Jeffrey Lipman
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 17, 2012
Editorial commentary: Closing the loop--a colistin clinical study to confirm dosing recommendations from PK/PD modelingJason A Roberts, Jeffrey Lipman
Clinical Pharmacokinetics|August 4, 2006
Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsisJason A Roberts, Jeffrey Lipman
Critical Care Medicine|February 25, 2009
Pharmacokinetic issues for antibiotics in the critically ill patientJason A Roberts, Jeffrey Lipman
Critical Care (London, England)|May 10, 2007
Conclusions regarding the efficacy of treatments for neuroleptic malignant syndrome should be tempered given poor quality data, regardless of the analysis conductedDarren M Roberts, Jason A Roberts
Pageof 69